SciSparc subsidiary NeuroThera Labs enrolls 26 children in SCI-210 autism trial
SPRC•Study design and next steps
Participants ages 5-18 receive 20 weeks of treatment. Key readouts track behavioral change, clinician-rated improvement, safety, and dose optimization.
NeuroThera plans to pursue commercialization in Israel first, subject to successful development and regulatory clearances.
Trial enrollment reaches 26 participants
SciSparc’s subsidiary NeuroThera Labs accelerated enrollment in its SCI-210 pediatric autism trial, reaching 26 participants toward a 60-child target.
The trial at Soroka Medical Center is testing a CBD plus CannAmide formulation versus CBD monotherapy in a double-blind, randomized, placebo-controlled design.
